Biomarin Pharmace…
USUSDBiomarin Pharmaceutical Inc (LSE:0HNC) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 4. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la Empresa
- Sitio Web
- biomarin.com
- Relaciones con los Inversores
- investors.biomarin.com/overview/default.aspx
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede Central
- NOVATO, United States
- Gestión
- Jean Jacques Bienaime
- Empleados
- 3 221
- Fundada
- 1997
- IPO
- 1999-07-23
- Acciones en Circulación
- 193.57 M a 2026-07-28
- Capital Flotante
- 192.63 M
- Capitalización Bursátil
- 10.71 mil M USD
- Insiders
- 0.34%
- Inversores Institucionales
- 103.8%
- Industria (SIC)
- Pharmaceutical Preparations
- Forma Jurídica
- XTIQ
- ISIN
- US09061G1013
- LEI
- NSLL8ITTRR0J5HEMR848
- P/E
- 281
- P/B
- 1.71
- FCF
- 738 M USD
- Deuda
- 4.19 mil M USD4.5 a. de FCF
- Resultados y FCF — para los 12 meses hasta 30.06.2026 (el último informe de la empresa).
- Beneficio Neto
- NAV
Descripción
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Bolsas y Tickers
| Bolsa | Ticker | Moneda | Precio | Tipo |
|---|---|---|---|---|
| US USA Stocks | BMRN principal | USD | 55.35 -0.72% | acciones ordinarias |
| LSE London Stock Exchange | 0HNC IOB | USD | 60.5 +0.00% | acciones ordinarias |
| MI Borsa Italiana (Milan) | 1BMRN secundaria | EUR | 49.02 -0.18% | acciones ordinarias |
| VI Vienna Stock Exchange | BMRN secundaria | EUR | 48.37 -2.58% | acciones ordinarias |
Noticias de Esta Semana
Comunicados de prensa desde la página web para inversores de la empresa, actualizados diariamente. Los enlaces conducen a la página web de la empresa. Los titulares están en el idioma original, como en la página web de la empresa.
Principales Accionistas
| Titular | Participación | Acciones | Fecha del Informe |
|---|---|---|---|
| Blackrock Inc. | 10.56% | 20.45 M | 2026-06-30 |
| Dodge & Cox Inc. | 7.67% | 14.84 M | 2026-06-30 |
| Primecap Management Comp… | 7.33% | 14.19 M | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 5.05% | 9.77 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.52% | 8.74 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.47% | 8.65 M | 2026-06-30 |
| NORGES BANK | 4.24% | 8.21 M | 2026-06-30 |
| State Street Corporation | 4.03% | 7.8 M | 2026-06-30 |
| Viking Global Investors,… | 3.93% | 7.62 M | 2026-06-30 |
| iShares Trust-iShares Co… | 3.5% | 6.77 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 6.14 M | 2026-06-30 |
| Vestal Point Capital, LP | 3.11% | 6.03 M | 2026-06-30 |
| AQR Capital Management,… | 2.94% | 5.7 M | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 2.67% | 5.17 M | 2026-06-30 |
| VANGUARD CHESTER FUNDS-V… | 2.57% | 4.97 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.29% | 4.43 M | 2026-06-30 |
| Fidelity Contrafund | 1.47% | 2.84 M | 2026-07-31 |
| Capital World Growth & I… | 1.33% | 2.58 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.32% | 2.55 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 2.22 M | 2026-06-30 |
| HARDY ALEXANDER (Chief E… | ≈0.11% | 218 887 | 2026-03-16 |
| MEIER RICHARD A (Directo… | ≈0.07% | 126 926 | 2025-12-30 |
| MUELLER BRIAN R (Chief F… | ≈0.06% | 125 431 | 2026-03-16 |
| GUYER CHARLES GREG (Chie… | ≈0.04% | 85 833 | 2026-03-16 |
| DAVIS GEORGE ERIC (Offic… | ≈0.03% | 61 003 | 2026-09-02 |
| FRIBERG GREGORY R (Offic… | ≈0.03% | 51 818 | 2026-05-07 |
| HOMBACH ROBERT J. CPA (D… | ≈0.03% | 49 360 | 2026-06-02 |
| DERE WILLARD H (Director… | ≈0.02% | 46 440 | 2026-06-02 |
| HUBBARD CRISTIN (Officer… | ≈0.02% | 44 790 | 2026-03-16 |
| ANDERSON ELIZABETH M (Di… | ≈0.02% | 41 940 | 2026-06-02 |
Inicia Sesión con Google